LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
XMT-2056: Mersana continues to escalate dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen ADC candidate targeting a novel HER2 epitope. GSK plc has an ...
The latest update is out from Mersana Therapeutics ( (MRSN)). Mersana Therapeutics, a biopharmaceutical company, is advancing its clinical trials for promising cancer treatments, XMT-1660 and XMT ...
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback